Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready • 1 patents granted in the last 365 days
Oncosol Limited currently has 1 pending office action in its portfolio. This action is being handled by 1 distinct examiner, WELLS, LAUREN QUINLAN. As the busiest examiner for the company, WELLS, LAUREN QUINLAN is managing the 1 pending action, which is the only action currently pending for the company. The record indicates 0 distinct art units, suggesting that the action is not currently associated with a specific unit in the provided data. This profile shows a simple prosecution landscape with a single point of contact at the patent office.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Multi-statute (no §101) | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| WELLS, LAUREN QUINLAN | 1 | 49.4% | +59.7% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 19027117 | NON-AQUEOUS ORAL SUSPENSION OF TEMOZOLOMIDE | WELLS, LAUREN QUINLAN | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 19027117 | NON-AQUEOUS ORAL SUSPENSION OF TEMOZOLOMIDE | WELLS, LAUREN QUINLAN | — |
| Art Unit | Apps |
|---|---|
| 1622 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 19027117 | NON-AQUEOUS ORAL SUSPENSION OF TEMOZOLOMIDE | WELLS, LAUREN QUINLAN | 1622 | §102§103§112Other | Non-Final OA | — | Pending | Jan 17, 2025 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialOncosol Limited has 1 pending office actions as of October 2026, spread across 1 art units and 1 examiners.
Lauren Quinlan Wells has the most, with 1 of Oncosol Limited's pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.